Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy.

Ziegler, Dan; Hanefeld, Markolf; Ruhnau, K J; Hasche, H; Lobisch, M; Schütte, Klemens; Kerum, Gorazd; Maleßa, R.

doi:10.2337/diacare.22.8.1296

Cited by 405 publications

(290 citation statements)

References 0 publications

Supporting

Mentioning

251

Contrasting

Unclassified

Order By: Relevance

“…The ALADIN III study showed that a 3-week i.v. treatment with ALA followed by a 6-month oral treatment could not demonstrate a prior specified effect on neuropathic symptoms, but it indicated some clinically meaningful effects on neuropathic deficits in the treatment of ALA (34). However, the Oral Pilot (ORPIL) study, although with a smaller population, showed that oral treatment with 600 mg ALA t.i.d.…”

Section: Discussionmentioning

confidence: 94%

“…So ALA should be considered as a good choice among pathogenetically oriented treatments of diabetic neuropathy. As ALA was first used therapeutically in Germany to treat diabetic neuropathy, there have been various controlled clinical trials assessing the efficacy of ALA in treating diabetic neuropathy (12,33,34,35,36,37). The findings of ALADIN study substantiated that i.v.…”

Section: Discussionmentioning

confidence: 96%

See 1 more Smart Citation

THERAPY OF ENDOCRINE DISEASE: A systematic review and meta-analysis of α-lipoic acid in the treatment of diabetic peripheral neuropathy

Han

Bai

Liu

et al. 2012

European Journal of Endocrinology

144

View full text Add to dashboard Cite

Objective: To evaluate the effects and safety of 300-600 mg a-lipoic acid (ALA) given i.v. for diabetic peripheral neuropathy (DPN). Methods: We searched the databases of Medline, Embase, and Cochrane central register of Controlled Trials and Chinese biological medicine for clinical trials of ALA in the treatment of DPN. Data were extracted to examine methodological quality and describe characteristics of studies. The primary outcomes were efficacy, median motor nerve conduction velocity (MNCV), median sensory nerve conduction velocity (SNCV), peroneal MNCV, and peroneal SNCV. Secondary outcomes were adverse events. Results: Fifteen randomized controlled trials met the inclusion criteria. The treatment group involved the administration of ALA 300-600 mg i.v. per day. And the control group used the same interventions except for ALA. Compared with the control group, nerve conduction velocities increased significantly in the treatment group. The weighted mean differences in nerve conduction velocities were 4.63 (95% confidence interval 3.58-5.67) for median MNCV, 3.17 (1.75-4.59) for median SNCV, 4.25 (2.78-5.72) for peroneal MNCV, and 3.65 (1.50-5.80) for peroneal SNCV in favor of the treatment group. The odds ratio in terms of efficacy was 4.03 (2.73-5.94) for ALA. Furthermore, no serious adverse events were observed during the treatment period. Conclusions:The results of this meta-analysis provide evidence that treatment with ALA (300-600 mg/day i.v. for 2-4 weeks) is safe and that the treatment can significantly improve both nerve conduction velocity and positive neuropathic symptoms. However, the evidence may not be strong because most of the studies included in this meta-analysis have poor methodological quality.

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 96%

THERAPY OF ENDOCRINE DISEASE: A systematic review and meta-analysis of α-lipoic acid in the treatment of diabetic peripheral neuropathy

Han

Bai

Liu

et al. 2012

European Journal of Endocrinology

144

View full text Add to dashboard Cite

show abstract

“…ALA has been considered to be safe and effective for treatment of symptomatic diabetic polyneuropathy [10,11]. The aim of the present study was to investigate the possible cardioprotective effect of α-lipoic acid in type 1 diabetic children and adolescents.…”

Section: Introductionmentioning

confidence: 99%

Alpha-Lipoic Acid Improves Subclinical Left Ventricular Dysfunction in Asymptomatic Patients with Type 1 Diabetes

Hegazy¹,

Tolba²,

Mostafa³

et al. 2013

Rev Diabet Stud

View full text Add to dashboard Cite

■ Abstract BACKGROUND:Oxidative stress plays an important role in the development of diabetic cardiomyopathy. Alpha-lipoic acid (ALA) is a powerful antioxidant that may have a protective role in diabetic cardiac dysfunction. AIM: We investigated the possible beneficial effect of alpha-lipoic acid on diabetic left ventricular (LV) dysfunction in children and adolescents with asymptomatic type 1 diabetes (T1D). SUB-JECTS AND METHODS: Thirty T1D patients (aged 10-14) were randomized to receive insulin treatment (n = 15) or insulin plus alpha-lipoic acid 300 mg twice daily (n = 15) for four months. Age and sex matched healthy controls (n = 15) were also included. Patients were evaluated with conventional 2-dimensional echocardiographic examination (2D), pulsed tissue Doppler (PTD), and 2-dimensional longitudinal strain echocardiography (2DS) before and after therapy. Glutathione, malondialdhyde (MDA), nitric oxide (NO), tumor necrosis factor-alpha (TNF-alpha), Fas ligand (Fas-L), matrix metalloproteinase 2 (MMP-2), and troponin-I were determined and correlated to echocardiographic parameters. RESULTS: Diabetic patients had significantly lower levels of glutathione and significantly higher MDA, NO, TNF-alpha, Fas-L, MMP-2, and troponin-I levels than control subjects. The expression of transforming growth factor beta (TGF-beta) mRNA in peripheral blood mononuclear cells was also increased in diabetic patients. Significant correlations of mitral e'/a' ratio and left ventricular global peak systolic strain with glutathione, MDA, NO, TNF-alpha, and Fas-L were observed in diabetic patients. Alpha-lipoic acid significantly increased glutathione level and significantly decreased MDA, NO, TNF-alpha, Fas-L, MMP-2, troponin-I levels, and TGF-beta gene expression. Moreover, alphalipoic acid significantly increased mitral e'/a' ratio and left ventricular global peak systolic strain in diabetic patients. CONCLUSION: These findings suggest that alpha-lipoic acid may have a role in preventing the development of diabetic cardiomyopathy in type 1 diabetes.

show abstract

“…Other options that limit end organ dysfunctions should also be considered, such as aspirin, blood pressure and lisinopril for kidney, heart, and vasculature protection. Multiple drugs and other compounds have been proposed in reducing or reversing DN, however none have found to be successful in comprehensive reviews, with polyneuropathy with the anti-oxidant alpha-lipoic acid as a prime failed example [47]. Sadly, medical management in peripheral DN is reduced to controlling the underlying illness and managing symptoms.…”

Section: Medical Managementmentioning

confidence: 99%

Peripheral Nervous System Involvement in Diabetes and Role of Rehabilitation

Jens¹,

Ahmed²

2016

Int J Neurorehabilitation Eng

View full text Add to dashboard Cite

Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy.

Cited by 405 publications

References 0 publications

THERAPY OF ENDOCRINE DISEASE: A systematic review and meta-analysis of α-lipoic acid in the treatment of diabetic peripheral neuropathy

THERAPY OF ENDOCRINE DISEASE: A systematic review and meta-analysis of α-lipoic acid in the treatment of diabetic peripheral neuropathy

Alpha-Lipoic Acid Improves Subclinical Left Ventricular Dysfunction in Asymptomatic Patients with Type 1 Diabetes

Peripheral Nervous System Involvement in Diabetes and Role of Rehabilitation

Contact Info

Product

Resources

About